Literature DB >> 20509908

Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania.

Edith A M Tarimo1, Anna Thorson, Thecla W Kohi, Joachim Mwami, Muhammad Bakari, Eric Sandström, Asli Kulane.   

Abstract

BACKGROUND: Results from HIV vaccine trials on potential volunteers will contribute to global efforts to develop an HIV vaccine. The purpose of this study among police officers in Dar es Salaam, Tanzania, was to explore the underlying reasons that induce people to enrol in an HIV vaccine trial.
METHODS: We conducted discussions with eight focus groups, containing a total of 66 police officers. The information collected was analyzed using interpretive description.
RESULTS: The results showed that participants were motivated to participate in the trial by altruism, and that the participants experienced some concerns about their participation. They stated that altruism in the fight against HIV infection was the main reason for enrolling in the trial. However, young participants were seriously concerned about a possible loss of close relationships if they enrolled in the HIV vaccine trial. Both men and women feared the effect of the trial on their reproductive biology, and they feared interference with pregnancy norms. They were unsure about risks such as the risks of acquiring HIV infection and of suffering physical harm, and they were unsure of the intentions of the researchers conducting the trial. Further, enrolling in the trial required medical examination, and this led some participants to fear that unknown diseases would be revealed. Other participants, however, saw an opportunity to obtain free health services.
CONCLUSIONS: We have shown that specific fears are important concerns when recruiting volunteers to an HIV vaccine trial. More knowledge is needed to determine participants' views and to ensure that they understand the conduct of the trial and the reasons it is being carried out.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20509908      PMCID: PMC2888745          DOI: 10.1186/1471-2458-10-292

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


  35 in total

Review 1.  First trial of the HIV-1 vaccine in Africa: Ugandan experience.

Authors:  Roy D Mugerwa; Pontiano Kaleebu; Peter Mugyenyi; Edward Katongole-Mbidde; David L Hom; Rose Byaruhanga; Robert A Salata; Jerrold J Ellner
Journal:  BMJ       Date:  2002-01-26

2.  Local knowledge and experiences of vaccination: implications for HIV-preventive vaccine trials in South Africa.

Authors:  Graham Lindegger; Michael Quayle; Moses Ndlovu
Journal:  Health Educ Behav       Date:  2006-05-31

3.  Pediatric HIV type 1 vaccine trial acceptability among mothers in Kenya.

Authors:  Carey Farquhar; Grace C John-Stewart; Francis N John; Marjory N Kabura; James N Kiarie
Journal:  AIDS Res Hum Retroviruses       Date:  2006-06       Impact factor: 2.205

Review 4.  The value of children in African countries: insights from studies on infertility.

Authors:  Silke J Dyer
Journal:  J Psychosom Obstet Gynaecol       Date:  2007-06       Impact factor: 2.949

5.  Why blacks do not take part in HIV vaccine trials.

Authors:  Demetrius L Moutsiakis; P Nancy Chin
Journal:  J Natl Med Assoc       Date:  2007-03       Impact factor: 1.798

6.  Strengths and challenges in the use of interpretive description: reflections arising from a study of the moral experience of health professionals in humanitarian work.

Authors:  Matthew R Hunt
Journal:  Qual Health Res       Date:  2009-09

7.  Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial.

Authors:  Jacqueline M O'Connell; Robert S Hogg; Keith Chan; Steffanie A Strathdee; Nancy McLean; Steve L Martindale; Brian Willoughby; Robert Remis
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-15       Impact factor: 3.731

8.  Willingness to participate in HIV vaccine trials among HIV-negative gay men in Sydney, Australia.

Authors:  Paul Van de Ven; Limin Mao; June Crawford; Garrett Prestage; Andrew Grulich; John Kaldor; Susan Kippax
Journal:  Int J STD AIDS       Date:  2005-04       Impact factor: 1.359

9.  Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities.

Authors:  R P Strauss; S Sengupta; S Kegeles; E McLellan; D Metzger; S Eyre; F Khanani; C B Emrick; K M MacQueen
Journal:  J Acquir Immune Defic Syndr       Date:  2001-01-01       Impact factor: 3.731

10.  Willingness of Chinese injection drug users to participate in HIV vaccine trials.

Authors:  Lu Yin; Yuanzhi Zhang; Han-Zhu Qian; Baoling Rui; Lijiang Zhang; Junling Zhu; Yongsheng Guan; Yunxia Wang; Qingchun Li; Yuhua Ruan; Yiming Shao
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

View more
  12 in total

1.  Conceptual framework for behavioral and social science in HIV vaccine clinical research.

Authors:  Chuen-Yen Lau; Edith M Swann; Sagri Singh; Zuhayr Kafaar; Helen I Meissner; James P Stansbury
Journal:  Vaccine       Date:  2011-08-05       Impact factor: 3.641

2.  Typologies of Altruistic and Financial Motivations for Research Participation.

Authors:  Lisa J Chin; Jacqueline A Berenson; Robert L Klitzman
Journal:  J Empir Res Hum Res Ethics       Date:  2016-10       Impact factor: 1.742

3.  The perceptions on male circumcision as a preventive measure against HIV infection and considerations in scaling up of the services: a qualitative study among police officers in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Joel M Francis; Deodatus Kakoko; Patricia Munseri; Muhammad Bakari; Eric Sandstrom
Journal:  BMC Public Health       Date:  2012-07-19       Impact factor: 3.295

4.  Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Muhammad Bakari; Fred Mhalu; Asli Kulane
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

5.  A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania.

Authors:  Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Muhammad Bakari; Eric Sandstrom; Fred Mhalu; Asli Kulane
Journal:  BMC Infect Dis       Date:  2011-10-24       Impact factor: 3.090

6.  Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I/II HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Patricia Munseri; Said Aboud; Muhammad Bakari; Fred Mhalu; Eric Sandstrom
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

7.  Motivations to participate in a Phase I/II HIV vaccine trial: A descriptive study from Dar es Salaam, Tanzania.

Authors:  E A M Tarimo; M Bakari; D C V Kakoko; T W Kohi; F Mhalu; E Sandstrom; A Kulane
Journal:  BMC Public Health       Date:  2016-02-24       Impact factor: 3.295

8.  Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis.

Authors:  Catherine Houghton; Maura Dowling; Pauline Meskell; Andrew Hunter; Heidi Gardner; Aislinn Conway; Shaun Treweek; Katy Sutcliffe; Jane Noyes; Declan Devane; Jane R Nicholas; Linda M Biesty
Journal:  Cochrane Database Syst Rev       Date:  2020-10-07

9.  A qualitative study of perceived risk for HIV transmission among police officers in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Thecla W Kohi; Muhammad Bakari; Asli Kulane
Journal:  BMC Public Health       Date:  2013-08-29       Impact factor: 3.295

10.  Gender aspects on HIV prevention efforts and participation in HIV vaccine trials among Police officers in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Deodatus C V Kakoko; Thecla W Kohi; Muhammad Bakari; Eric Sandstrom; David Siyame; Fred Mhalu; Asli Kulane
Journal:  BMC Public Health       Date:  2018-07-21       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.